Accessibility Menu
Bio-Techne logo

Bio-Techne(NASDAQ) TECH

Market Cap$11.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)+13,303%
5 Year-39%
1 Year+23%
1 Month+1%
$72.10
+0.67%
+0.48Today
Bio-Techne last closing stock price
MetricPriceDate
Last closeUSD 71.622026-07-27
Bio-Techne stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.03%USD 71.642026-07-20
1 month+0.87%USD 71.002026-06-26
3 month+34.09%USD 53.412026-04-28
Year to date+22.17%USD 58.622025-12-31
1 year+22.58%USD 58.432025-07-25
3 year-13.19%USD 82.502023-07-28
5 year-38.55%USD 116.552021-07-28
Since inception+13,302.9%USD 0.531992-06-15

Bio-Techne Financials at a Glance

Market Cap

$11.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.21B

Net Income (TTM)

$109.57M

EPS (TTM)

$0.70

P/E Ratio

102.87

Dividend

$0.32

Beta (Volatility)

1.15 (Average)

Price

$72.10

Volume

7,785,767.748

Open

$71.76

Previous Close

$72.07

Daily Range

$71.76 - $72.16

52-Week Range

$43.20 - $72.16

Estimated Earnings Date

Aug 5, 2026

TECH News

BullBearImage-Red.png

Stock Market Today, June 25: Bio-Techne Surges After Merck KGaA Announces $73-Per-Share Cash Acquisition Offer

Josh Kohn-LindquistJun 25, 2026
SellAlert-Green.png

Is Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?

Andy GouldMar 13, 2026
Foolcom-Featured.png

Bio-Techne (TECH) Q4 EPS Rises 8.2%

Motley Fool Markets TeamAug 6, 2025
man with cup listening to wall GettyImages-511535378

Better Know Biotech: 2 Stocks You Ought to Know About

Todd CampbellMay 16, 2018

Techne Keeps Dividend Steady

Rich DupreyAug 6, 2013

Techne's Upcoming Earnings: What You Need To Know

Seth JaysonJul 29, 2013

Will Techne Whiff on Revenues Next Quarter?

Seth JaysonJun 19, 2013

Techne to Acquire Diagnostics Firm for $104 Million

Rich DupreyJun 18, 2013
Page 1

TECH: Motley Fool Moneyball Superscore

61

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bio-Techne

Bio-Techne makes tools that help scientists study diseases and create new medicines. Their products allow researchers to see how proteins and genes work inside the body. These tools are used by drug companies and doctors to improve patient care.

What Bio-Techne Sells

  • Protein Sciences: Specialized biological liquids, antibodies, and testing kits used for cell and gene therapy and drug research.
  • Diagnostics and Spatial Biology: Tools that let doctors run clinical tests and study how genes are arranged within tissue samples.
  • Consumables: Single-use products like proteins and reagents that accounted for $235 million in sales for Q2 2026.
  • Instruments: Automated machines used in labs for protein analysis and molecular testing.
  • Services: Custom manufacturing and laboratory help that generated $22 million in sales for the quarter ended December 31, 2025.

Growth and New Directions

  • Entered an investment in Spear Bio for $15 million in July 2024 to support new testing technologies.
  • Acquired a 19.9% stake in Wilson Wolf in March 2023, a maker of cell culture devices, for $232 million.
  • Divested the Exosome Diagnostics business in September 2025 to MDxHealth to focus on core profitable areas.
  • Engaged in enterprise-wide restructuring starting in fiscal 2025 to optimize global manufacturing and improve operating margins.

Operational Strengths

Bio-Techne operates a global distribution network that serves both the research and clinical diagnostic markets. By owning brands like R&D Systems and Novus Biologicals, the company maintains a deep portfolio of biological content used in scientific investigations worldwide.

The Recent Numbers

  • Net sales for Q2 2026 were $295.9 million, down 0.4% compared to the same period in 2025.
  • Operating income reached $54.5 million in Q2 2026, a 14.9% increase from $47.4 million in the prior year.
  • Net income rose to $38 million for the quarter ended December 31, 2025, up 8.9% year-over-year.
  • Free cash flow for Q2 2026 was $76.5 million, representing a 1.3% decrease from the previous year.

Bottom Line

Bio-Techne has transitioned from a reagent supplier to a broad life sciences company with automated instruments and diagnostic tools. This evolution and its focus on high-growth areas like cell therapy support its role in global medical research.

AI Generated • Apr 21, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

3,100

CEO

Kim Kelderman

Website

www.bio-techne.com

Headquarters

Minneapolis, MN 55413, US

TECH Financials

Key Financial Metrics (TTM)

Gross Margin

64.96%

Operating Margin

12.70%

Net Income Margin

9.05%

Return on Equity

5.49%

Return on Capital

4.33%

Return on Assets

4.30%

Earnings Yield

0.97%

Dividend Yield

0.45%

Payout Ratio

45.47%

Stock Overview

Market Cap

$11.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

156.57M

Volume

7.79M

Avg. Volume

4.83M

Financials (TTM)

Gross Profit

$786.49M

Operating Income

$153.75M

EBITDA

$257.98M

Operating Cash Flow

$294.86M

Capital Expenditure

-$25.26M

Free Cash Flow

$269.60M

Cash & ST Invst.

$209.82M

Total Debt

$290.32M

Bio-Techne Performance Analysis

Bio-Techne annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 1,105,599,000N/A
20232023-06-30USD 1,136,702,0002.8%
20242024-06-30USD 1,159,060,0002.0%
20252025-06-30USD 1,219,635,0005.2%
Bio-Techne sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-300.2%
Q12025-09-30-9.6%
Q22025-12-313.3%
Q32026-03-315.3%
Bio-Techne annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD 1.66N/A
20232023-06-30USD 1.766.3%
20242024-06-30USD 1.05-40.7%
20252025-06-30USD 0.46-56.1%
Bio-Techne sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30-178.6%
Q12025-09-30318.2%
Q22025-12-31N/A
Q32026-03-3133.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$311.42M

-1.5%

Gross Profit

$208.29M

-2.9%

Gross Margin

66.88%

N/A

Market Cap

$11.21BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.62M

N/A

Employees

3,100

N/A

Net Income

$51.06M

+126.0%

EBITDA

$98.62M

+45.3%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$209.82M

+49.2%

Total Debt

$290.32M

-31.4%

Accounts Receivable

$217.92M

-8.1%

Inventory

$201.18M

+5.3%

Long Term Debt

$276.14M

-32.6%

Short Term Debt

$14.18M

+0.9%

Return on Assets

4.30%

N/A

Return on Invested Capital

6.41%

N/A

Free Cash Flow

$77.58M

+150.3%

Operating Cash Flow

$86.66M

+110.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BMRNBioMarin Pharmaceutical Inc.
$62.07+2.99%
CORTCorcept Therapeutics Incorporated
$94.19+3.37%
MDGLMadrigal Pharmaceuticals, Inc.
$538.80-2.26%
QGENQiagen N.V.
$42.28+2.92%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$86.30-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.22-0.01%
JBLUJetBlue Airways
$6.00+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.15-0.01%

Questions About TECH

What is the current price of Bio-Techne?

Bio-Techne is trading at $72.07 per share.

What is the 52-week range for Bio-Techne?

Over the past 52 weeks, Bio-Techne has traded between $43.20 and $72.16.

How much debt does Bio-Techne have?

As of the most recent reporting period, Bio-Techne reported total debt of $290.32M.

How much cash does Bio-Techne have on hand?

Bio-Techne reported $209.82M in cash and cash equivalents in its most recent financial results.

What is Bio-Techne’s dividend yield?

Bio-Techne currently has a dividend yield of 0.45%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services